SCHEMBL24625396

SCHEMBL24625396

NC(=O)c1sccc1Nc1nc(Cl)ncc1C(F)(F)F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IRAK4 Q9NWZ3 2/20 0.45
▸ CDC7 O00311 1/20 0.45
▸ ROCK2 O75116 1/20 0.45
▸ MAP4K4 O95819 1/20 0.45
▸ PIM1 P11309 1/20 0.45
▸ PRKACA P17612 1/20 0.45
▸ CDK7 P50613 1/20 0.45
▸ CDK9 P50750 1/20 0.45
▸ HIPK2 Q9H2X6 1/20 0.45
▸ PLK1 P53350 2/20 0.41
▸ KDR P35968 1/20 0.40
▸ AURKB Q96GD4 1/20 0.40
▸ PTK2 Q05397 2/20 0.39
▸ KIT P10721 3/20 0.39
▸ FLT3 P36888 3/20 0.39
▸ MAPK3 P27361 5/20 0.38
▸ ULK1 O75385 1/20 0.36
▸ GSK3A P49840 1/20 0.36
▸ GSK3B P49841 1/20 0.36
▸ MAPK10 P53779 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24625780 0.84 AURKA (0.44) IRAK4CDC7PLK1KDRAURKB
SCHEMBL24625379 0.84 EGFR (0.45) IRAK4CDC7ROCK2MAP4K4PIM1
SCHEMBL24625395 0.82 PKM (0.41) IRAK4PIM1PLK1MAPK3MAPK10
SCHEMBL30757908 0.82 MEN1 (0.43) IRAK4CDC7ROCK2MAP4K4PIM1
SCHEMBL24625390 0.82 MEN1 (0.43) IRAK4CDC7ROCK2MAP4K4PIM1
SCHEMBL24625779 0.79 PLK1 (0.41) IRAK4PIM1PLK1MAPK3MAPK10
SCHEMBL24625778 0.79 IGF1R (0.41) PLK1KDRMAPK10
SCHEMBL1202633 0.79 CDC7 (0.70) IRAK4CDC7ROCK2MAP4K4PIM1
SCHEMBL1703868 0.77 KDR (0.71) IRAK4CDC7ROCK2MAP4K4PIM1
SCHEMBL29985004 0.75 ULK1 (0.58) IRAK4CDC7ROCK2MAP4K4PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025887-A1 THIENYL AND CYCLOALKYL AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF SINAI HEALTH SYSTEM (CA) 2024-01-25 — — US disclosed
US-20240025887-A1 THIENYL AND CYCLOALKYL AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF SINAI HEALTH SYSTEM (CA) 2024-01-25 — — US disclosed
US-20240025887-A1 THIENYL AND CYCLOALKYL AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF SINAI HEALTH SYSTEM (CA) 2024-01-25 — — US disclosed
WO-2022147620-A1 THIENYL AND CYCLOALKYL AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2022-07-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025887-A1 THIENYL AND CYCLOALKYL AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF NUAK1, NUAK2, PNKP IRAK4 714/4885CDC7 248/4885ROCK2 1829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback